TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice

Authors: Fay, Magdalena, Sievers, Cem, Robbins, Yvette, Yang, Xinping, Huynh, Angel, Redman, Jason M., Hodge, James W., Schlom, Jeffrey, Gulley, James L., Allen, Clint T., Craveiro, Marco

Source: In iScience 16 August 2024 27(8)

Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach

Authors: Hoke, Austin T.K., Takahashi, Yoko, Padget, Michelle R., Gomez, Javier, Amit, Moran, Burks, Jared, Bell, Diana, Xie, Tongxin, Soon-Shiong, Patrick, Hodge, James W., Hanna, Ehab Y., London, Nyall R., Jr

Source: In Translational Oncology June 2024 44

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

Authors: Fabian, Kellsye P., Hodge, James W.

Source: In Molecular Therapy - Oncolytics 17 December 2021 23:266-276

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.

Authors: Zahavi, David¹ (AUTHOR) david.zahavi@nih.gov, Hodge, James W.¹ (AUTHOR) jh241d@nih.gov

Source: International Journal of Molecular Sciences. May2023, Vol. 24 Issue 10, p8871. 15p.

Subject Terms: *ADENOSINES, *PROGRAMMED cell death 1 receptors, *IMMUNOTHERAPY, *TUMOR microenvironment, *IMMUNE checkpoint proteins, *CANCER invasiveness, *CELL physiology

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

Authors: Park, So-Jin, Ye, Wenda, Xiao, Roy, Silvin, Christopher, Padget, Michelle, Hodge, James W., Van Waes, Carter, Schmitt, Nicole C.

Source: In Oral Oncology August 2019 95:127-135

Rationale for IL-15 superagonists in cancer immunotherapy

Authors: Knudson, Karin M., Hodge, James W., Schlom, Jeffrey, Gameiro, Sofia R.

Source: Expert opinion on biological therapy. 20(7):705-709

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100110695955.0x000001&indx=1&recIds=ETOCvdc_100110695955.0x000001

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models

Authors: Franks, S. Elizabeth, Fabian, Kellsye P., Santiago-Sánchez, Ginette, Wolfson, Benjamin, Hodge, James W.

Source: Oncoimmunology. 11(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100168533684.0x000001&indx=1&recIds=ETOCvdc_100168533684.0x000001

Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer

Authors: Morisada, Megan, Moore, Ellen C., Hodge, Rachel, Friedman, Jay, Cash, Harrison A., Hodge, James W., Mitchell, James B., Allen, Clint T.

Source: In Oral Oncology August 2017 71:87-94

Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses.

Authors: Larkin, Riley M., Lopez, Diana C., Robbins, Yvette L., Lassoued, Wiem, Canubas, Kenneth, Warner, Andrew, Karim, Baktiar, Vulikh, Ksenia, Hodge, James W., Floudas, Charalampos S., Gulley, James L., Gallia, Gary L., Allen, Clint T., London Jr., Nyall R.

Source: Journal of Translational Medicine; 5/31/2024, Vol. 22 Issue 1, p1-16, 16p

Subject Terms: NEUROBLASTOMA, MYELOID-derived suppressor cells, KILLER cells, HLA-DR antigens, CHEMOKINES, SKULL base

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence.

Authors: Lopez, Diana C., Fabian, Kellsye P., Padget, Michelle R., Robbins, Yvette L., Kowalczyk, Joshua T., Lassoued, Wiem, Pastor, Danielle M., Allen, Clint T., Gallia, Gary L., Gulley, James L., Hodge, James W., London Jr., Nyall R.

Source: Frontiers in Oncology; 2024, p1-11, 11p

Subject Terms: CHORDOMA, CANCER stem cells, DISEASE relapse, IMMUNOTHERAPY, CELL lines

A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab

Authors: Fujii, Rika, Schlom, Jeffrey, Hodge, James W.

Source: Journal of neurosurgery. 128(5):1419-1427

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN615808335&indx=1&recIds=ETOCRN615808335

An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression

Authors: Fujii, Rika, Jochems, Caroline, Tritsch, Sarah R., Wong, Hing C., Schlom, Jeffrey, Hodge, James W.

Source: Cancer immunology, immunotherapy. 67(4):675-689

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100125516108.0x000001&indx=1&recIds=ETOCvdc_100125516108.0x000001

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.

Authors: Santiago-Sánchez, Ginette S., Fabian, Kellsye P., Hodge, James W.

Source: Cancer Biology & Therapy; 2024, Vol. 25 Issue 1, p1-20, 20p

Next Generation Therapeutic Strateg‐Es: Evolving cancer immunotherapy through agents that Engage, Expand and Enable the anti‐tumor immune response

Authors: Wolfson, Benjamin, Hodge, James W.

Source: Immunomedicine. 1(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100130135744.0x000001&indx=1&recIds=ETOCvdc_100130135744.0x000001

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti‐PD‐L1 antibody

Authors: Jochems, Caroline, Hodge, James W., Fantini, Massimo, Tsang, Kwong Y., Vandeveer, Amanda J., Gulley, James L., Schlom, Jeffrey

Source: International journal of cancer. 141(3):583-593

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100108768011.0x000001&indx=1&recIds=ETOCvdc_100108768011.0x000001

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7

Authors: Tsang, Kwong Y., Fantini, Massimo, Fernando, Romaine I., Palena, Claudia, David, Justin M., Hodge, James W., Gabitzsch, Elizabeth S., Jones, Frank R., Schlom, Jeffrey

Source: Vaccine. 35(19):2605-2611

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100045939788.0x000001&indx=1&recIds=ETOCvdc_100045939788.0x000001

Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities

Authors: Garnett-Benson, Charlie, Hodge, James W., Gameiro, Sofia R.

Source: In Seminars in Radiation Oncology January 2015 25(1):46-53

A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines

Authors: Donahue, Renee N., Duncan, Brynn B., Fry, Terry J., Jones, Barry, Bachovchin, William W., Kiritsy, Christopher P., Lai, Jack H., Wu, Wengen, Zhao, Peng, Liu, Yuxin, Tsang, Kwong-Yok, Hodge, James W.

Source: In Vaccine 30 May 2014 32(26):3223-3231

Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy

Authors: Wattenberg, Max M., Fahim, Ahmed, Ahmed, Mansoor M., Hodge, James W.

Source: Radiation Research, 2014 Aug 01. 182(2), 126-138.

Access URL: http://www.jstor.org/stable/24545389

In Vivo Effects of Lattice Radiation Therapy on Local and Distant Lung Cancer: Potential Role of Immunomodulation

Authors: Kanagavelu, Saravana, Gupta, Seema, Wu, Xiaodong, Philip, Sakhi, Wattenberg, Max M., Hodge, James W., Couto, Mariluz D., Chung, Kristina D., Ahmed, Mansoor M.

Source: Radiation Research, 2014 Aug 01. 182(2), 149-162.

Access URL: http://www.jstor.org/stable/24545391